Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival.
Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print].
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
Merz M et al. Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.
Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Chim CS et al. Hematol Oncol. 2014 Jan 29. doi: 10.1002/hon.2131. [Epub ahead of print].
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Bensinger WI et al. Bone Marrow Transplant. 2014 Jan 13. doi: 10.1038/bmt.2013.219. [Epub ahead of print].
A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Richardson PG et al. Blood. 2014 Jan 15. [Epub ahead of print].
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Richardson PG et al. Blood. 2014 Jan 13. [Epub ahead of print].